ECE2009 Poster Presentations Diabetes and Cardiovascular (103 abstracts)
Biphasic insulin aspart 30/70 improves glycaemic control in patients with type 2 diabetes: clinical practice experience from Indian subgroup of the IMPROVE study™
AG Unnikrishnan 1 , Siddharth Shah 2 , Arthur Asirvatham 3 , Praful Chakkarwar 5 , Ashok Moharana 5 & Dheeraj Kapoor 4
1Amrita Institute of Medical Sciences, Cochin, Kerala, India; 2Bhatia Hospital, Mumbai, Maharashtra, India; 3Madurai Medical College, Madurai, Tamilnadu, India; 4Artemis Health Institute, Gurgaon, Haryana, India; 5Novo Nordisk, Bangalore, India.
Aims & objectives: IMPROVE™ is a 6-month, multi-national, prospective, observational study, assessing the safety and efficacy of biphasic insulin aspart 30/70 (BiAsp 30) in patients with type 2 diabetes.
Methods: We present the efficacy data from the Indian cohort of IMPROVE study. A total of 17 995 subjects entered the study and 16 942 subjects completed the study. BiAsp 30 was initiated and dose was adjusted at the physician’s discretion, reflecting everyday practice. Efficacy analysis set (EAS) includes 16 322 subjects. Efficacy was assessed by change in mean HbA1c, proportion of subjects achieving HbA1c targets (≤6.5%, <7%, target set by treating physicians), change in FBG, change in PPBG and change in FBG variability following 26 weeks of treatment.
Results: In comparison to baseline, there were significant reductions in mean HbA1c (n=15 624, 9.33 to 7.33%, P<0.001), FBG (n=14 935, 191 to 120 mg/dl, P<0.001), FBG variability (n=59, 21 to 11 mg/dl, P<0.001) and 2-hour post breakfast PPBG (n=10 319, 277 to 171 mg/dl, P<0.001) at the end of 26 weeks treatment. Significant improvement was also seen in proportion of subjects achieving HbA1c ≤6.5% (19%), HbA1c<7% (40%) and HbA1c target set by treating physicians (32%).
Conclusions: In this real life practice study, BiAsp 30 effectively improved glycemic parameters. Initiation of BiAsp 30 treatment significantly reduced mean HbA1c, FBG, 2-hour PPBG and FBG variability. There were also significant improvements in proportions of subjects achieving HbA1c targets. In conclusion, BiAsp 30 is an effective option for treating type 2 diabetes in Indian subjects.
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more